Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model
- PMID: 29159777
- DOI: 10.1007/s11060-017-2685-4
Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model
Abstract
We assessed prognostic factors in relation to OS from progression in recurrent glioblastomas. Retrospective multicentric study enrolling 407 (training set) and 370 (external validation set) adult patients with a recurrent supratentorial glioblastoma treated by surgical resection and standard combined chemoradiotherapy as first-line treatment. Four complementary multivariate prognostic models were evaluated: Cox proportional hazards regression modeling, single-tree recursive partitioning, random survival forest, conditional random forest. Median overall survival from progression was 7.6 months (mean, 10.1; range, 0-86) and 8.0 months (mean, 8.5; range, 0-56) in the training and validation sets, respectively (p = 0.900). Using the Cox model in the training set, independent predictors of poorer overall survival from progression included increasing age at histopathological diagnosis (aHR, 1.47; 95% CI [1.03-2.08]; p = 0.032), RTOG-RPA V-VI classes (aHR, 1.38; 95% CI [1.11-1.73]; p = 0.004), decreasing KPS at progression (aHR, 3.46; 95% CI [2.10-5.72]; p < 0.001), while independent predictors of longer overall survival from progression included surgical resection (aHR, 0.57; 95% CI [0.44-0.73]; p < 0.001) and chemotherapy (aHR, 0.41; 95% CI [0.31-0.55]; p < 0.001). Single-tree recursive partitioning identified KPS at progression, surgical resection at progression, chemotherapy at progression, and RTOG-RPA class at histopathological diagnosis, as main survival predictors in the training set, yielding four risk categories highly predictive of overall survival from progression both in training (p < 0.0001) and validation (p < 0.0001) sets. Both random forest approaches identified KPS at progression as the most important survival predictor. Age, KPS at progression, RTOG-RPA classes, surgical resection at progression and chemotherapy at progression are prognostic for survival in recurrent glioblastomas and should inform the treatment decisions.
Keywords: Conditional random forest; Cox model; Decision tree; Glioblastoma; Karnofsky performance status; Overall survival; Prognostic models; Random survival forest; Recurrence; Recursive partitioning analysis; Surgery.
Similar articles
-
Implant volume as a prognostic variable in brachytherapy decision-making for malignant gliomas stratified by the RTOG recursive partitioning analysis.Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):963-8. doi: 10.1016/s0360-3016(01)01746-1. Int J Radiat Oncol Biol Phys. 2001. PMID: 11704318
-
Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?J Neurooncol. 2017 Nov;135(2):285-297. doi: 10.1007/s11060-017-2573-y. Epub 2017 Jul 19. J Neurooncol. 2017. PMID: 28726173
-
Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article.J Neurosurg. 2011 Aug;115(2):220-9. doi: 10.3171/2011.3.JNS10495. Epub 2011 May 6. J Neurosurg. 2011. PMID: 21548745
-
The impact of hyperglycemia on survival in glioblastoma: A systematic review and meta-analysis.Clin Neurol Neurosurg. 2018 Jul;170:165-169. doi: 10.1016/j.clineuro.2018.05.020. Epub 2018 May 19. Clin Neurol Neurosurg. 2018. PMID: 29803727
-
Relationship between cognitive function and prognosis in glioblastoma.CNS Oncol. 2013 Mar;2(2):195-201. doi: 10.2217/cns.13.5. CNS Oncol. 2013. PMID: 25057978 Free PMC article. Review.
Cited by
-
Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models.Cancers (Basel). 2023 Sep 8;15(18):4478. doi: 10.3390/cancers15184478. Cancers (Basel). 2023. PMID: 37760448 Free PMC article.
-
Do presenting symptoms predict treatment decisions and survival in glioblastoma? Real-world data from 1458 patients in the Swedish brain tumor registry.Neurooncol Pract. 2024 Apr 23;11(5):652-659. doi: 10.1093/nop/npae036. eCollection 2024 Oct. Neurooncol Pract. 2024. PMID: 39279780 Free PMC article.
-
Management of Recurrent Glioblastomas: What Can We Learn from the French Glioblastoma Biobank?Cancers (Basel). 2022 Nov 9;14(22):5510. doi: 10.3390/cancers14225510. Cancers (Basel). 2022. PMID: 36428604 Free PMC article.
-
Dynamic Susceptibility Perfusion Imaging for Differentiating Progressive Disease from Pseudoprogression in Diffuse Glioma Molecular Subtypes.J Clin Med. 2021 Feb 5;10(4):598. doi: 10.3390/jcm10040598. J Clin Med. 2021. PMID: 33562558 Free PMC article.
-
Management, functional outcomes and survival in a French multicentric series of 118 adult patients with cerebellar glioblastoma.J Cancer Res Clin Oncol. 2021 Jun;147(6):1843-1856. doi: 10.1007/s00432-020-03474-6. Epub 2021 Jan 5. J Cancer Res Clin Oncol. 2021. PMID: 33399987 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical